ArticleActa parasitologica2021
Morphological and Molecular Identification of Emerged Lophomonas blattarum Infection in Mazandaran Province, Northern Iran: First Registry-Based Study.
Article in Acta parasitologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Pulmonary infection due to emergingSAGE open medical case reports · 2026Article
- Coexistence of Tuberculosis and Lophomoniasis in a Patient With Alzheimer's Disease.Respirology case reports · 2025Article
- Development and Validation of In-House Conventional and Multiplex PCR Methods for the Detection and Identification of Lophomonas spp.: An Innovative Approach.Journal of clinical laboratory analysis · 2025Article
- Low occurrence of pulmonary lophomoniasis among cigarette smokers: An analysis of risk factors based on registry data.Lung India : official organ of Indian Chest Society · 2025Article
- Effect of Antibiotic Therapy againstTanaffos · 2025Article
- Pathogen-Agnostic Advanced Molecular Diagnostic Testing for Difficult-to-Diagnose Clinical Syndromes-Results of an Emerging Infections Network Survey of Frontline US Infectious Disease Clinicians, May 2023.Open forum infectious diseases · 2024Article
- First Molecular Evidence of Emerging Lophomonas Pathogen Among Patients Suspected of Having Pulmonary Tuberculosis in Mazandaran Province, Northern Iran.Acta parasitologica · 2024Article
- Imaging patterns of Lophomonas blattarum infection in the respiratory tract: a registry-based analysis.BMC infectious diseases · 2024Article
- Severe lophomoniasis in a patient with diabetes and past history of COVID-19 in Central Iran: case report.The Journal of international medical research · 2024Article
- Lophomonas blattarum-like organism in bronchoalveolar lavage from a pneumonia patient: current diagnostic scheme and polymerase chain reaction can lead to false-positive results.Parasites, hosts and diseases · 2023Article
- Geospatial Analysis and Molecular Epidemiologic Study of Emerging Pulmonary Lophomoniasis in Iran: A National Registry-Based Study.Journal of parasitology research · 2023Article
- Molecular proof forRespirology case reports · 2022Article
- Article
- First molecular approach to diagnose paediatric pulmonary lophomoniasis: A case series.Respirology case reports · 2022Article
- Cavitary pulmonary lesions following emerging lophomoniasis: A novel perspective.Respirology case reports · 2022Article
- First report of emerged pulmonary lophomoniasis in two Afghanian medical tourists.Clinical case reports · 2022Article
- First Co-morbidity of Lophomonas blattarum and COVID-19 Infections: Confirmed Using Molecular Approach.Acta parasitologica · 2022Article
- First report ofRespirology case reports · 2022Article
- Molecular evidence of upper and lower respiratory infection due toClinical case reports · 2022Article
- High Occurrence of EmergedInterdisciplinary perspectives on infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIn the last decade, several cases of bronchopulmonary lophomoniasis (BPL) have been recorded. Little information is available about epidemiological aspects on Lophomonas infection among BPL patients. The present study was aimed to investigate the prevalence of Lophomonas spp. infection in patients who were referred to the Iranian National Registry Center for Lophomoniasis (INRCL), using morphological and molecular tests. SUBJECTS AND
methodsWe examined patients enrolled in the INRCL from 2017 to 2019 at the Mazandaran University of Medical Sciences, northern Iran. All bronchoalveolar lavage fluid (BALF) and two nasal discharges of the patients were examined by both microscopic and small-subunit ribosomal RNA (SSU rRNA) PCR methods. To confirm the species of Lophomonas, two positive samples were sequenced.
resultsIn this study, 321 specimens (including 319 BALF and 2 nasal discharges) were microscopically examined. Lophomonas spp. was found in 45(14%) (n = 44 BAL; n = 1 nasal discharge). The mean age of infected patients was 54.9 ± 17.1 years. The following morphological characteristics were observed in both fresh and Papanicolaou-stained smears to identify Lophomonas spp. All microscopically positive specimens were confirmed with genus-specific PCR technique. The obtained sequences were deposited in Gen Bank under the accession numbers (MN243135-36). The BLAST analysis of our two sequences with the only available sequence in the Gen Bank of the Thailand strain of L. blattarum, showed identity of 99-100% and 98.51%, respectively.
conclusionTo the best of our knowledge, this is the first registry-based study regarding lophomoniasis worldwide. According to our study, the conventional PCR test is an available and reliable tool for confirming the Lophomonas parasite in clinical samples. Moreover, the results confirmed that L. blattarum is circulating at least in our region.
Indexed as
Identifiers
34115281What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.